ECWM-1

Study Design: Phase II, randomized, multicenter, international trial

Patients: treatment naive WM patients

Treatment: DRC versus Bortezomib-DRC

Status of the Study: completed published (Buske et. al. JCO 2023), final analysis pending

Sponsor: University Hospital of Ulm, PI Christian Buske

further information

Publication